{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:52:23Z","timestamp":1772718743865,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"DOI":"10.7759\/cureus.40127","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T14:01:36Z","timestamp":1686232896000},"source":"Crossref","is-referenced-by-count":3,"title":["Galcanezumab-Induced Myasthenia Gravis-Like Symptoms"],"prefix":"10.7759","author":[{"given":"Adnan A","family":"Mubaraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2022-S105","article-title":"Myasthenia gravis in clinical practice","volume":"80","author":"Estephan EP","year":"2022","unstructured":"Estephan EP, Baima JP, Zambon AA. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr. 2022, 80:257-65. 10.1590\/0004-282X-ANP-2022-S105","journal-title":"Arq Neuropsiquiatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst F","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021, 22:128. 10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1002-7","article-title":"Galcanezumab: first global approval","volume":"78","author":"Lamb YN","year":"2018","unstructured":"Lamb YN. Galcanezumab: first global approval. Drugs. 2018, 78:1769-75. 10.1007\/s40265-018-1002-7","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010143","article-title":"Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data","volume":"12","author":"Pavelic AR","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022, 12:10.3390\/cells12010143","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-018-1153-8","article-title":"Neuromuscular junction morphology and gene dysregulation in the wobbler model of spinal neurodegeneration","volume":"66","author":"Ratliff WA","year":"2018","unstructured":"Ratliff WA, Saykally JN, Kane MJ, Citron BA. Neuromuscular junction morphology and gene dysregulation in the wobbler model of spinal neurodegeneration. J Mol Neurosci. 2018, 66:114-20. 10.1007\/s12031-018-1153-8","journal-title":"J Mol Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5414\/CP204340","article-title":"Ocular myasthenia gravis-like symptoms associated with erenumab: case report","volume":"61","author":"Marusic S","year":"2023","unstructured":"Marusic S, Andric J, Cigrovski Berkovic M. Ocular myasthenia gravis-like symptoms associated with erenumab: case report. Int J Clin Pharmacol Ther. 2023, 61:178-80. 10.5414\/CP204340","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli B","year":"2019","unstructured":"Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019, 20:66. 10.1186\/s10194-019-1018-8","journal-title":"J Headache Pain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160991-galcanezumab-induced-myasthenia-gravis-like-symptoms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:31Z","timestamp":1707508891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160991-galcanezumab-induced-myasthenia-gravis-like-symptoms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.40127","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}